Mercury Laboratories Limited

MERCURYLAB6

INE947G01011

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:59 2024-07-02 EDT			5-day change	1st Jan Change
960 ^INR	-2.89%		+8.47%	-6.76%

05-28	Mercury Laboratories Limited Recommends Dividend for the Year 2023-24	CI
05-28	Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Mercury Laboratories Limited Appoints Janki R Shah as Director

September 30, 2020 at 05:04 am

Mercury Laboratories Limited appointed Janki R Shah as Director of the Company at the Annual General Meeting of the Company held on September 29, 2020.

Latest news about Mercury Laboratories Limited

Mercury Laboratories Limited Recommends Dividend for the Year 2023-24	05-28	CI
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Mercury Laboratories Names COO	11-08	MT
Mercury Laboratories Limited Announces Promotion of Saurabh Mittal as Chief Operating Officer	11-08	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31,2023	23-09-28	CI
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-05	CI
Mercury Laboratories Limited Recommends Dividend for the Year 2022-23	23-05-05	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Mercury Laboratories Limited Approves Creation of New Facility for Manufacturing Small Volume Parenteral(SVPs) At Jarod	22-11-12	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2022	22-09-27	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
Mercury Laboratories Limited Recommends Dividend for the Year 2022	22-05-26	CI
Mercury Laboratories Limited Announces Resignation of Kinjal Khandelwal as Company Secretary and Compliance Officer	22-01-21	CI
Mercury Laboratories Limited Approves Appointment of Mr. Ashish Vasavada, as Chief Financial Officer	21-10-21	CI
Mercury Laboratories Approves Interim Dividend and Final Dividend for the Year Ended March 31, 2021	21-09-28	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-10	CI
Mercury Laboratories : Crisil Affirms FB+ Rating on Mercury Laboratories' Fixed Deposits; Outlook Stable	21-06-17	MT
Mercury Laboratories' : CFO Tenders Resignation	21-05-27	MT
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-05-27	CI
Mercury Laboratories Limited Recommends Dividend for Year Ended March 31, 2021	21-05-27	CI
Mercury Laboratories Limited Announces Resignation of Enu Khandelwal as CFO with Effect from June 22, 2021	21-05-27	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-11	CI

Chart Mercury Laboratories Limited

Duration

Period

More charts

Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. The Company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, among others. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCURY LABORATORIES LIMITED	-6.76%	14.21M
MERCK KGAA	+4.09%	70.89B
KYOWA KIRIN CO. LTD.	+17.03%	9.08B
YUHAN CORPORATION	+11.92%	4.53B
SK BIOPHARMACEUTICALS CO., LTD.	-21.91%	4.47B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+22.70%	3.97B
INDIVIOR PLC	+2.19%	2.08B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.95%	2.04B
BETTA PHARMACEUTICALS CO., LTD.	-36.00%	1.94B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-45.17%	1.77B